Teladoc Health (TDOC) Stock Jumps As Q3 Results Spotlight Cash Flow

Teladoc Health just ripped higher, jumping 26.9% to US$8.73 after its Q3 2026 report, as traders rushed back into a stock that had been under pressure for months. At first glance the excitement focuses on adjusted earnings power, with adjusted EBITDA of US$79 million and free cash flow of US$76 million grabbing the spotlight.

Stepping back a little tells a different story. Revenue for the quarter came in at US$605.1 million, and the business still reported a loss. The real action is on the balance sheet and debt, where rising cash and low net leverage now matter more than a one-day price pop.

Love Teladoc Health's free cash flow but concerned that the business is still posting losses? Check out the list of solid balance sheet and fundamentals stocks (22 results) for companies that pair healthier earnings profiles with stronger balance sheets.

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$605.1 million vs. US$626.4 million (decline of 3.4%)
• Net Income/Loss (Q3 2026 vs. Q3 2025): loss of US$26.9 million vs. loss of US$49.5 million (loss narrowed 45.6%)
• Basic EPS (Q3 2026 vs. Q3 2025): loss of US$0.15 per share vs. loss of US$0.28 per share (per share loss improved 47.1%)
• Integrated Care Adjusted EBITDA Margin (Q3 2026 vs. Q3 2025): 18.8% vs. approximately 17.0% (margin improved by about 1.8 percentage points)

Earnings show a loss, yet Teladoc Health's latest quarter also produced meaningful free cash flow, which is what many valuation focused investors watch most closely. If you anchor on Teladoc Health's cash flows rather than reported earnings, the stock could be a solid 26% undervalued.

Evaluating Teladoc’s Execution Milestones Against The Bull Case

"The main thing that has to go right is that Teladoc Health successfully completes the revenue mix shifts in Integrated Care and BetterHelp while sustaining cost discipline so that improved segment margins and free cash flow remain supported."

Teladoc Health is at least partially delivering on that blueprint. Integrated Care revenue edged higher to US$398 million with margin at 18.8%, helped by stronger chronic care and international contributions. BetterHelp is under pressure, yet insurance revenue reached US$32 million in Q3 and advertising spend declined 27%, which aligns with the cost discipline angle. Consolidated free cash flow of US$76 million in the quarter supports the cash generation side of the thesis, even while the business still reports a loss.

One Narrative disagrees with today's price. → See where this Narrative says Teladoc Health should trade.

Teladoc Bear Case: Mix Drag Still Bites

The cautious view argues that Teladoc Health’s mix shift and compliance load could blunt margin progress even when cost cuts look strong.

"Bearish analysts expect Teladoc Health to keep facing rising compliance burdens, operational complexity and reimbursement pressure that limit the benefit of cost savings and weigh on long-term profitability."

Q3 margins present a mixed picture. Integrated Care reported an 18.8% adjusted EBITDA margin, which does not fit well with the idea that cost savings are failing to materialize. BetterHelp is where the bear case remains most prominent. Revenue declined 12.8% and segment margin was 2.2%, even after a 27% reduction in advertising, so the lower margin insurance mix continues to be a notable headwind.

Hunt For Mispriced Cash Generators

Teladoc Health just showed how quickly sentiment can swing after a single quarter. The real opportunity is finding stocks that could be undervalued before the market corrects them.

• Company 1 - 15% below our estimate - rides a swelling data center project backlog that is pulling communications and infrastructure work into multi year contracts.
• Company 2 - 40% below our estimate - turns a growing backlog for solar trackers into a platform sale that now pulls through storage and inverter projects.
• Company 3 - 37% below our estimate - uses a new manufacturing build out to secure higher margin film and installation work directly from automakers and dealers.

That is three of the list. See all 30 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com